Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months

intervention study intervention arm Inclusion criteria: 1. Documented HIV-1 infection 2. Age 50 years or older 3. Stable on ART ≥ 3/12 4. Undetectable plasma HIV RNA (\< 50 copies/ml) 5. Moderate or high Framingham CVD risk score 6. Life expectancy \> 12 months 7. Regular patient under care of non-director physician 8. Willing to adhere to pharmacological CVD risk reduction intervention 9. Willing to participate in lifestyle change advice intervention Exclusion criteria for intervention study 1. Life expectancy \< 1yr 2. Unable to undertake exercise 3. Drug dependency 4. Cognitive impairment affecting ability to participate in study 5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5mI U/ml) 6. Women of childbearing potential who are unwilling to use reliable contraception for the duration of the study Inclusion criteria for intervention study control arm (Group 2) 1. Documented HIV-1 infection 2. Age 50 years or older 3. Stable on ART ≥3/12 4. Undetectable plasma HIV RNA (\<50 copies/ml) 5. Moderate or high Framingham risk score (\>10%) 6. Life expectancy \> 12 months 7. Regular patient under care of non-director physician